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Genetic studies have revealed natural amino acid variations within the human papillomavirus (HPV) type 16 E6 oncoprotein. To address the
functional significance of E6 polymorphisms, 10 HPV16 E6 variants isolated from cervical lesions of Swedish women were evaluated for their
activities in different in vitro and in vivo assays relevant to the carcinogenic potential of E6. Small differences between E6 prototype and variants,
and among variants, were observed in transient expression assays that assessed p53 degradation, Bax degradation, and inhibition of p53
transactivation. More variable levels of activities were exhibited by the E6 proteins in assays that evaluated binding to the E6-binding protein
(E6BP) or the human discs large protein (hDlg). The E6 prototype expressed moderate to high activity in the above assays. The L83V
polymorphism, previously associated with risk for cancer progression in some populations, expressed similar levels of activity as that of the E6
prototype in most functional assays. On the other hand, L83V displayed more efficient degradation of Bax and binding to E6BP, but lower binding
to hDlg. Results of this study indicate that naturally occurring amino acid variations in HPV16 E6 can alter activities of the protein important for
its carcinogenic potential.
© 2006 Elsevier Inc. All rights reserved.Keywords: HPV polymorphism; HPV 16 E6 variants; E6 protein functions; p53Arg/Pro; Bax; E6BP; hDLGIntroduction
Development of anogenital cancer is strongly associated
with the infection by certain types of human papillomavirus
(HPV) referred to as high-risk or oncogenic among whom
HPV16 has the highest prevalence rate (50–70% in cervical
cancer). However, less than 5% of high-risk HPV infected
women develop cervical intraepithelial neoplasia (CIN), and
only 10–20% of CIN progress into invasive carcinoma,
indicating that additional viral or nonviral risk factors are also
involved in determining the fate of HPV16 lesions (Zur-
Hausen, 1996; Burd, 2003). Several studies showed that viral
factors such as persistence of the HPV infection, continuous⁎ Corresponding author. Fax: +972 3 6409160.
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doi:10.1016/j.virol.2006.01.038expression of the viral oncogenes, E6 and E7, integration of
viral DNA into the host cell chromosome, and inactivation of
the E2 gene are key events for the progression from CIN to
cancer. Host factors such as HLA genotype and polymorphism
of the p53 gene may also be important (reviewed in Giannoudis
and Herrington, 2001; Ferenczy and Franco, 2002; Burd, 2003;
Baseman and Koutsky, 2005). One viral factor about which an
increasing amount of information is being gathered is HPV
sequence variations. Independent genetic and epidemiological
studies demonstrated the existence of natural variations in the
HPV genome (reviewed in Bernard, 2005). For HPV 16, five
phylogenetic lineages of the virus have been defined. These are
classified based on their suspected origin as European (E),
Asian (As), Asian–American (AA), African-1 (Af1), and
African-2 (AF-2) (Yamada et al., 1995, 1997). The prototype
HPV16 belongs to the European lineage. In addition to the
lineage specific variations, other nucleotide variations within
Fig. 1. Expression of epitope-tagged HPV16 E6 prototype and E6-variant
proteins in COS cells. COS cells were transfected with 5 μg of the E6 prototype
(PT) or E6-variant (V) plasmid DNA together with 1 μg of the GFP plasmid. At
48 h post-transfection, cells were analyzed for expression of the fusion proteins
by immunoblot analysis. E6 fusion proteins were detected with the HA antibody.
Band intensities were quantified by densitometric scanning, relative to the GFP
that was used as control for transfection efficiency. Representative blots are
shown.
217H. Lichtig et al. / Virology 350 (2006) 216–227lineages were also identified (Giannoudis and Herrington, 2001;
Hildesheim and Wang, 2002). Several early studies provided
evidence on a link between intra-type variation in the E6
oncogene and persistent infection (Londesborough et al., 1996;
Xi et al., 1995, 1997). In other studies, the association between
HPV16 variants and progression of cervical neoplasia was
investigated. Initial studies carried out in a Swedish cohort
found that invasive cancers carried almost exclusively HPV16
variants and rarely harbored the prototype. The most frequent
E6 variation was seen at residue 83 (L83V). This polymorphism
was detected alone or in combination with others in 88% of ICC
and 44% of CIN III cases (Zehbe et al., 1998b). However, in
other studies in different European populations, the L83V
variant was not clearly associated with cervical cancers (Zehbe
et al., 1998a; Bontkes et al., 1998; Nindl et al., 1999; Brady et
al., 1999; van Duin et al., 2000). The differences in the results
may reflect genetic differences between populations, particu-
larly genetic variations in HLA, or could be due to the
overwhelming predominance of the low-risk European lineage
in the European population studies (Zehbe et al., 1998a, 2001).
Studies conducted in more diverse populations (Xi et al., 1997,
2002; Villa et al., 2000; Berumen et al., 2001; Tornesello et al.,
2004) have demonstrated a two to nine-fold increased risk of
cervical cancer and high-grade lesions when infected with non-
European HPV16 variants (reviewed by Hildesheim and Wang,
2002).
The majority of HPV 16 variations have been identified
within the E6 gene that encodes a key viral oncoprotein. The E6
oncoprotein interacts with a variety of cellular proteins involved
in different signaling pathways, of which the best known is p53
(reviewed in Thomas et al., 1999; Mantovani and Banks, 2001;
Munger and Howley, 2002). Many of the E6 interacting proteins
were described as targets for E6-dependent degradation
(reviewed in Scheffner and Whitaker, 2003). Alteration of the
levels or activity of these proteins could have major impact on
tumorigenesis. Variations within the E6 gene leading to amino
acid changes could alter the biological or immunogenic
properties of the encoded protein (Ellis et al., 1995; Zehbe et
al., 2003). Little is known about the functional consequence of
sequence variations with respect to the E6 protein activity.
Previous studies have analyzed only few HPV 16 variants and
showed that amino acid variations can alter its ability to
abrogate serum/calcium-dependent differentiation, induce p53
degradation in vitro (Conrad Stoppler et al., 1996) and regulate
tumorigenesis by Notch signaling and oncogenic Ras (Chakra-
barti et al., 2004).
Here, we have performed a detailed and comprehensive
functional analysis of ten E6 naturally occurring E6 variants
whose prevalence in pre-malignant and malignant tissues was
previously determined in three different populations (Zehbe et
al., 2001; Kammer et al., 2002). Variants were evaluated for
their biochemical activities in various in vivo and in vitro assays
that are relevant to the carcinogenic potential of E6. These
include the ability of the proteins to induce p53 degradation and
inhibit p53 transactivation (TA), induce Bax degradation, and
bind to the E6-binding protein (E6BP) and the human discs
large tumor suppressor protein (hDlg).Results
Activity of HPV16 E6 variants in p53 degradation
Targeting of p53 for degradation is believed to be an
essential event in HPV-mediated cellular transformation
(reviewed in Thomas et al., 1999). We evaluated the ability of
the E6 variants to inactivate p53 in transient coexpression
assays using plasmids that express p53 and the E6 proteins. The
epitope-tagged E6 proteins were expressed from the pJS55
vector. To verify the expression of the recombinant proteins,
plasmids were transfected into COS cells which allow high
levels of plasmid replication and expression. Proteins were
detected by immunoblot analysis using the anti-HA antibody.
Transfection efficiencies were monitored by cotransfection of
the pJS-GFP expression plasmid and determination of the levels
of the green fluorescent protein in the same filter. Representa-
tive experiments are shown in Fig. 1. The prototype E6 and
most E6-variant proteins were detected with the antibody used.
Expressions of the E6-variant proteins were at similar levels and
comparable to that of the E6 prototype. Variant 10 could not be
detected due to a termination codon mutation in the HA tag.
Another plasmid clone of variant 10 with an intact tag showed
similar levels of expression as compared to the E6 prototype
(data not shown).
Degradation activities of the E6 proteins were tested in the
p53-deficient H1229 cell line. Two polymorphic forms of p53
bearing either proline or argenine at codon 72 (Harris et al.,
1986) were used in these assays. In a previous report, the p53
variant bearing argenine at codon 72 was shown to be more
218 H. Lichtig et al. / Virology 350 (2006) 216–227susceptible to the E6-mediated degradation in vivo (Storey et
al., 1998). DNAs of the prototype E6 or E6-variant proteins
were cotransfected with the p53 plasmid, and levels of the p53
protein were determined in cell extracts prepared after 48 h by
Western blot. Transfection efficiencies were monitored by
cotransfection of the pJS-GFP expression plasmid and
determination of the levels of the green fluorescent protein in
the same filter. Fig. 2a shows degradation assays carried out
with 1 μg of p53 Arg or p53 Pro with increasing amounts of
the E6 prototype (0.5–7 μg). Dose-dependent degradation of
both polymorphic p53 proteins was exhibited by the E6
prototype. Degradation of p53 Arg and p53 Pro was at
comparable levels. Similar results were obtained in other
repetitive assays (data not shown). In subsequent experiments,
we compared the activities of the E6 variants. Transfection into
H1299 cells was carried out with 1 μg p53 and 5 μg of the E6-
variant plasmids, this excess was used to ensure coexpression
of E6 in all p53-transfected cells. Figs. 2b and c show two
representative assays carried out with p53 Arg or p53 Pro,
respectively. Fig. 2d and Table 2 summarize the collated resultsFig. 2. Activity of the E6 prototype and variant proteins in p53 Arg and p53 Pro deg
expression plasmid, 5 μg or as otherwise indicated of the E6 prototype (PT) or E6-va
48 h, and equal amounts of protein were separated by SDS-PAGE. Proteins were de
were quantified by densitometric scanning and normalized relative to the GFP. (a) C
prototype. (b–d) Degradation of p53 Arg and p53 Pro by the E6-variant proteins.
panels b and c. The average values of degradation activities obtained from 4–5 inde
Values of the relative mean activity, as compared to the PT activity (1), are shownof p53 degradation activities from multiple independent
transfection assays.
All E6 proteins exhibited high activity in p53 degradation
with similar levels towards p53 Arg and p53 Pro. Average
degradation activities ranged between 66 and 87%. Whereas
degradation activities were at comparable levels for most E6
proteins, including the prototype E6, we observed reduced
activity compared to the E6 prototype of variant 2 towards p53
Pro and, to a lesser extent, towards p53 Arg (0.78 and 0.89 of
the PT mean activity, respectively) (Fig. 2d). The differences in
p53 Pro degradation between variant 2 and the prototype as well
as between variant 2 and the variants 4, 8, and 10 were
statistically significant (P b 0.05) (Table 2). Slightly lower
degradation activity of p53 Arg was exhibited also by variant 3
(0.86 of the PT mean activity), while variant 7 showed lower
activity than prototype towards p53 Pro (0.85 of the PT mean
activity). Additional transfection experiments carried out with
lower amounts of the E6-variant and p53 plasmids (0.5 μg of
each plasmid) showed a similar pattern of plasmids activities
(data not shown).radation in vivo, in H1299 cells. Cells were cotransfected with 1 μg of the p53
riant plasmid (V), and 1 μg of the GFP plasmid. Cell lysates were prepared after
tected by Western blot analysis with the indicated antibodies. The levels of p53
omparison of p53 Arg and p53 Pro degradation by different amounts of the E6
Autoradiographs of two blots representative for each p53 variant are shown in
pendent assays with standard deviations are shown in the histogram in panel d.
below the bars.
Fig. 3. Inhibition of p53 Arg and p53 Pro-mediated transactivation by the E6
prototype and E6-variant proteins. H1299 cells were transfected with 0.5 μg of
p53, 0.5 μg of Renilla luciferase and 0.5 μg or as otherwise indicated of the E6-
variant DNA. Luciferase activity was determined in cell extracts prepared after
48 h. (a) Comparison of the inhibition of p53 Arg and p53 Pro by different
amounts of the E6 prototype. (b) Inhibition of p53 Arg and p53 Pro TA by E6-
variant proteins. The average values of TA inhibition ± standard deviations
obtained from 3–5 independent assays with p53 Arg and p53 Pro are shown in
the histogram in panel b. Values of the relative mean activity, as compared to the
PT activity (1), are shown below the bars.
Table 1
Isolation of the indicted variants from cervical lesions was previously described
(Zehbe et al., 2001; Kammer et al., 2002)
Variant Genotype prototype Amino acids Genetic code
1 R10G Argenine→Glycine AGA→GGA
2 K11T Lysine→Threonine AAG→ACG
3 N58S Aspargin→Serine AAT→AGT
4 R10G/L83V Argenine→Glycine AGA→GGA
Leucine→Valine TTG→GTG
5 I27R/L83V Isoleucine→Argenine ATA→AGA
Leucine→Valine TTG→GTG
6 Q14H/H78Y/L83V Glutamine→Histidine CAG→CAT
Histidine→Tyrosine CAT→TAT
Leucine→Valine TTG→GTG
7 R48W Argenine→Tryptophan CGG→TGG
8 L83V Leucine→Valine TTG→GTG
9 R8Q Argenine→Glutamine CGA→CAA
10 R10I/Q14D/I27T/
A61G/H78Y
Argenine→Isoleucine ATA→AGA
Glutamine→Aspartic acid CAG→GAT
Isoleucine→Threonine ATA→ACA
Alanine→Glycine GCT→GGA
Histidine→Tyrosine CAT→TAT
219H. Lichtig et al. / Virology 350 (2006) 216–227Downregulation of p53 transcriptional activity by HPV16 E6
variants
The physical association of E6 proteins of the high-risk HPV
types (HPV16 and HPV18) with p53 prevents binding to DNA
and results in abrogation of p53 transcription modulatory
functions (review by Thomas et al., 1999). In some studies, E6
inhibition of p53 transactivation was shown to be separable
from the ability of E6 to target p53 for degradation (Crook et al.,
1994; Thomas et al., 1995). More recent studies provided
evidence that E6 proteins from the high-risk HPVs possess an
alternative mechanism for downregulation of p53 transcription,
i.e., by targeting the CBP/p300 (Patel et al., 1999; Zimmermannet al., 1999). Activities of the E6-variant proteins in inhibition
of p53 TAwere evaluated in coexpression assays using the p53-
deficient H1299 carcinoma cells. Cells were transfected with
the p53 reporter plasmid which directs expression of the firefly
luciferase from the human mdm2 (hmdm2) promoter, the
Renilla luciferase plasmid that was used as a control for
transfection efficiency and the E6 variants as indicated. Fig. 3a
presents a representative assay showing dose-dependent
inhibition of luciferase activity induced by p53 Arg or p53
Pro with the E6 prototype. Transactivation activity of both p53
polymorphic proteins was inhibited by E6 at similar levels.
Activity of the variants was tested in subsequent assays using
0.5 μg of p53 and 0.5 μg of the E6-variant test plasmids. Fig. 3b
and Table 1 summarize the collated results obtained for the E6
proteins from multiple transfection experiments. The TA
activity of p53Arg was inhibited by 48–76% whereas that of
p53 Pro was by 33–74%. The prototype E6 showed high
inhibition activity towards both p53 variants with mean values
of 60% and 73% inhibition of p53 Pro and p53 Arg,
respectively. The differences in p53 Arg and p53 Pro inhibition
by the prototype, as well as other variants, were not statistically
significant. Variant 2 showed the lowest activity both towards
p53 Arg (48%) and p53 Pro (33%), and the differences from the
prototype activities (0.65 and 0.56 of the PT mean activity) were
statistically significant (Fig. 3b and Table 2). V2 showed
significantly lower activity as compared to other variants as well
(Table 2). Slightly reduced activities towards p53 Pro were also
exhibited by variant 7 (56%) and variant 9 (49%) (0.95 and 0.83
of the PT mean activity, respectively) (Fig. 3b), whereas
variants 6 and 7 showed lower activities than the prototype
towards p53 Arg (48% inhibition by both) (0.66 of the PT mean
activity) (Fig. 3b). The differences of variants 6 and 7 from the
prototype in p53 Arg inhibition were statistically significant
(Table 2). Slightly increased inhibitory activity towards p53 Pro
was exhibited by variants 4, 6, and 10 (1.20–1.25 of the PT
Table 2
Comparison of the activities of HPV16 E6 variants in different functional assays
E6 protein p53 Degradationa Inhibition of p53
transactivationa
Bax
degradationa
Binding
to
E6BPb
Binding
to
hDlgb
Arg Pro Arg Pro
Prototype ++++ ++++ +++ +++ +++ +++ ++
1. R10G ++++ ++++ +++ +++ ⁎ ++ ++ ⁎⁎ ++
2. K11T +++ +++ ⁎⁎ ++ ⁎⁎ + ⁎⁎ +++ +++ ⁎ ++
3. N58S +++ +++ +++ +++ ⁎ +++ ++ ⁎ +
4. R10G/L83V ++++ ++++ ⁎ +++ +++ ⁎ ++ +++ ⁎ ++
5. I27R/L83V +++ +++ +++ +++ ⁎ +++ ++++ ⁎ +++
6. Q14H/H78Y/L83V +++ +++ ++ ⁎⁎ +++ ⁎ ++ +++ ⁎ ++
7. R48W +++ +++ ++ ⁎⁎ ++ ⁎ ++ + ⁎⁎ ++
8. L83V ++++ ++++ ⁎ +++ +++ ⁎ +++ ⁎ ++++ ⁎ +
9. R8Q +++ ++++ +++ ++ ⁎ +++ + ⁎⁎ ++
10. R10I/Q14D/I27T/A61G/H78Y +++ ++++ ⁎ +++ ⁎ +++ ⁎ ++ ⁎ +++ ⁎ ++
a Percent degradation or inhibition of transactivation: N80% 4+; 60–80%, 3+; 40–60%, 2+; 20–40%,+.
b Relative percent or binding: N8%, 5+; 6–8% 4+, 4–6%, 3+, 2–4%, 2+; 1–2%, +.
* Significant difference from other variants (Pv b 0.05).
** Significant difference from PT (Pv b 0.05).
220 H. Lichtig et al. / Virology 350 (2006) 216–227activity); however, only the differences from V2 were
statistically significant. Thus, variant 2 is significantly less
active than other variants in both p53 degradation and inhibition
of p53 transactivation.
Activity of HPV16 E6-variant proteins in Bax degradation
The loss of molecular pathways that mediate apoptosis has
been implicated as an important event in tumor progression in a
number of systems. Recently, we showed that HPV16 induces
the degradation of Bax, a proapoptotic protein, in vivo
(Shnitman-Magal et al., 2005). Degradation of Bax is atFig. 4. In vivo Bax degradation assay with the E6 prototype and E6-variant proteins. H
plasmid, 1 μg of the GFP plasmid and the indicated amounts of the E6 plasmid. Ce
PAGE. Proteins were detected by Western Blot analysis. The levels of Bax were quan
of Bax with different amounts of the E6 prototype. (b, c) Degradation of Bax by the E6
of the E6-variant DNA. The average values of the degradation activities obtained by
panel c. Values of the relative mean activities, as compared to the PT activities (1),moderate levels as compared to the degradation of p53 and may
not be induced by direct interaction between the proteins
(Shnitman-Magal et al., 2005). Degradation activities of the E6
variants were evaluated by transfection into 293T cells of Bax
expression plasmid together with the E6-variant expression
plasmid and determination of the levels of the remaining Bax by
immunoblot analysis. Fig. 4a shows the results of a represen-
tative experiment with increasing amounts of the E6 prototype
(2–12 μg) demonstrating a dose-dependent degradation. Fig. 4b
shows the results of a representative experiment carried out with
the E6 prototype and selected variant proteins after transfection
of the cells with two different amounts of DNA. Fig. 4c showsuman 293T cells were cotransfected with 2 μg of the SFFV-Bax HA expression
ll lysates were prepared after 48 h, and equal amounts were separated by SDS-
tified by densitometric scanning and normalized relative to GFP. (a) Degradation
-variant proteins. (b) Autoradiograph of a representative assay with two amounts
5 μg (3–4 assays) and 10 μg DNA (4–6 assays) are shown in the histogram in
are shown below the bars.
Fig. 5. Stability of E6 proteins synthesized in vitro in wheat germ extract. 35S-
labeled E6 prototype and E6-variant proteins synthesized in WGE were
incubated at 25 °C. Samples were removed at the indicated time points and
analyzed by SDS-PAGE. Autoradiographs of representative assays are shown.
Fig. 6. In vitro association of E6BP with the E6 prototype and E6-variant
proteins. Glutathione-Sepharose beads containing 2 μg GST or GST-E6BP
fusion proteins were mixed with 35S-labeled in vitro translated E6-variant
proteins in 300 μl LSAB. After 2-h incubation and washes, the bound products
were separated by SDS-PAGE. One microliter of the 35S-labeled translation
product was fractionated separately before binding (input protein (a)).
Percentage of E6-variant protein bound to E6BP (b) was determined by
densitometric scanning of the bands and normalization relative to the level of the
recovered beads (c). A representative assay is shown. Collated results of binding
from 4–5 independent assays for each E6 protein are shown in panel d. Values of
the relative mean binding, as compared to the PT binding (1), are shown below
the bars.
221H. Lichtig et al. / Virology 350 (2006) 216–227the collated results of multiple transfection experiments. As
indicated, all tested proteins were active in Bax degradation.
The average degradation induced by 5 μg (10 μg ) of the E6-
variant DNA ranged between 28 and 54% (53–75%). The E6
prototype showed moderate to high activity (30 and 61%
degradation by 5 and 10 μg, respectively). Variant 5 and variant
8 showed relatively higher activity as compared to the E6
prototype and certain other variants. Variants 10 exhibited
relatively lower activity (Fig. 4c and Table 2). In transfection
assays carried out with 5 μg of the E6-variant DNA, the
differences in the mean activities of V5 (54%) and V8 (54%)
relative to the PT (30%) and V10 (28%) were statistically
significant (Fig. 4c). In assays carried out with 10 μg DNA only
the difference between V8 and V10 (75 and 53%, respectively)
was statistically significant (Table 2).
Activity of HPV16 E6-variant proteins in binding to E6BP
A well-known target of E6 is the calcium-binding protein
E6BP, also termed ERC55 (Chen et al., 1995). Only the E6
proteins of the high-risk HPVs bind to E6BP, but they do not
induce its degradation. The significance of the interaction
between E6 and E6BP for cellular transformation is yet
unknown. E6BP belongs to the family of multiple EF-hand,
low-affinity calcium-binding proteins that are localized to the
secretory pathway of mammalian cells. These proteins are
involved in signaling pathways that control cell growth and
differentiation (reviewed in Honore and Vorum, 2000). The
interaction of the E6-variant protein with E6BP was tested in
pull-down assays. The E6BP-GST fusion that encodes the C-
terminal 211 amino acids of E6BP (Chen et al., 1995) was used
for binding. Two micrograms of GST-E6BP and GST proteins,
bound to Sepharose beads, were reacted with the in vitro
translated 35S-labeled E6-variant proteins. Stability of the E6-
variant proteins, translated in vitro, was first examined by
monitoring the amounts of the proteins that remain in the
translation mix upon incubation at 25 °C for 3 h. Fig. 5 shows a
representative assay carried out with the E6 prototype and
variant proteins. All proteins translated at adequate amounts,
and no major changes in their levels were detected uponincubation for up to 3 h in 25 °C, indicating their stability in
vitro.
Figs. 6a–c show a representative experiment carried out with
the E6 prototype and selected E6 variants. Fig. 6d shows the
collated results of assays carried out with all E6 proteins. The
results indicated that all E6 proteins were capable of binding to
GST-E6BP. Binding to GST-E6BP was at variable levels. Mean
binding activities ranged between 1.6% (V1) and 7.8% (V5) of
the input protein. The prototype E6 exhibited moderate to high
activity (5.5%). Lower activities than the prototype were
exhibited by variants 1, 3, 4, 7, 9 (1.6–4.3%). The differences
in binding activities of variants 1, 7, and 9 from that of the
prototype were statistically significant (0.29–0.45 of the PT
mean activity) (Fig. 2d, Table 2). Higher activities than the
prototype were exhibited by variants 2, 5, and 8 (6.3–7.8%).
The differences from the prototype mean activity were not
statistically significant, but some of the differences between the
222 H. Lichtig et al. / Virology 350 (2006) 216–227high and low binding proteins were statistically significant
(Table 2). The L83V variant (V8) exhibited relatively high
binding activity to E6BP when present as sole variation (V8)
(6.55%) or in combination with the I27K (V5) (7.8%). Yet,
lower activity was exhibited by variant 4 that carried in addition
to the L83V variation the R10G change that reduced its activity.
The R10G mutation is present in variant 1 as sole mutation and
this variant displayed low binding activity to E6BP (2.5%).
Activity of HPV16 E6-variant proteins in binding to the human
discs large tumor suppressor
The high-risk HPV E6 proteins have been shown to interact
with several different PDZ domain-containing proteins includ-
ing the hDlg/SAP97 (Lee et al., 1997; Kiyono et al., 1997) E6
interaction targets the proteins for proteosomal degradation
(Gardiol et al., 1999; Pim et al., 2000; Thomas et al., 2001). The
interaction of E6 is mediated through a PDZ-binding motif (xT/
SxV) present in the C-terminal domain of all the high-risk E6
proteins. This domain has been shown to be important for the
transforming function of E6 in rodent cells (Kiyono et al., 1997;
Thomas et al., 2005) and for the induction of epithelial
hyperplasia in transgenic mice (Nguyen et al., 2003). Even
though all E6-variant proteins contain an intact PDZ domain,
we wished to determine whether amino acid alteration in N-
terminal region of E6 alter the binding capacity to hDlg. TheFig. 7. In vitro association of hDlg with E6 prototype and E6-variant proteins.
Experiments were carried out as described in the legend to Fig. 6 except that
GST-hDlg beads were used. A representative assay is shown panels a–c. The
average percents of E6-variant binding to hDlg ± standard deviations are shown
in panel d. Data are from 3–4 experiments for each protein.interaction with hDlg was tested in pull-down assays using a
GST-hDlg fusion protein (Lee et al., 1997) and in vitro
translated E6-variant proteins. Assays were carried out as
described above. Binding to GST-hDlg was tested in multiple
independent experiments. Fig. 7a shows a representative assay
carried out with the E6 prototype and variants 6–10. Fig. 7b
shows the collated results of multiple pull-down assays. All
tested proteins were capable of binding to GST-hDlg, albeit at a
low efficiency. Binding to GST-hDlg was less efficient as
compared to binding to E6BP and required longer exposure
periods of the gels (3 times longer). The relative mean binding
activities ranged between 1.6 and 4%. The prototype E6 showed
an average binding activity of 3%. Variants 5, 6, and 7 showed
higher binding to hDlg (4, 3.8, 3.5% respectively), while
variants 3 and 8 showed lower binding activities (1.95% and
1.6%, respectively) than the prototype. None of the differences
detected from the prototype, or among variants, was statistically
significant (P b 0.05).
Discussion
This study is the first to compare the activities of HPV16 E6
proteins encoded by the prototype and naturally occurring
variants in different functional assays.
Ten variants of HPV16 E6 were investigated. The distribu-
tion of these variants in cervical precursor lesions and cancer
was previously determined, in 3 different cohorts from Sweden,
the Czech Republic, and Italy (Zehbe et al., 2001; Kammer et
al., 2002). In all three populations, variant 8 (L83V) and
prototype E6 were the predominant types. As indicated before,
an opposite correlation between L83V presentation and disease
severity was observed in the different populations. In Swedish
women, the prevalence of V8 increased with the grade of the
lesion, whereas in Czech and Italian women, it decreased
(Zehbe et al., 2001; Kammer et al., 2002). Except for L83V,
each of the other variants analyzed in the present study showed
overall low presentation in the previously studied cohorts and
was detected at rates of 0–2.4%, except for V6 that showed a
higher prevalence (7.7%) in the Italian population (Zehbe et al.,
2001, Kammer et al., 2002). These “minor types” were mainly
detected in high-grade lesions and invasive carcinomas (Zehbe
et al., 2001).
Results of the study herein showed that all E6 proteins were
active in the functional assays employed. More uniform patterns
of activity with small differences among variants were exhibited
by the proteins in assays that tested p53 degradation, inhibition
of p53 transactivation, and degradation of Bax. As levels of
expression of the E6-variant proteins could not be determined in
the transfected cells (H1299 or 293T), differences in protein
stability/expression levels could possibly account for the
differences observed in protein activity. More variable levels
of activity were however exhibited in assays that evaluated
binding to E6BP and hDlg.
Inactivation of p53 is considered to be a major importance in
the carcinogenic process induced by E6 (reviewed in Thomas et
al., 1999). Two functions were evaluated in this study: the
ability to target p53 for degradation and the ability to inhibit p53
223H. Lichtig et al. / Virology 350 (2006) 216–227transactivation. Degradation and inhibition of transactivation
were tested with the two codon 72 polymorphic forms, p53 Arg
and p53 Pro. Similar levels of degradation and inhibition of
transactivation towards both polymorphic forms were exhibited
by all E6-variant proteins. In a previous study, p53 Arg was
shown to be more sensitive as compared to p53 Pro for E6-
mediated degradation in vivo (Storey et al., 1998). Inability to
detect this difference in our degradation assays could possibly
result from the large excess of the E6 plasmid used in most
degradation assays (five-fold), even though similar data were
obtained in assays that used lower amounts and ratio of E6 to
p53 (data not shown). Another possible explanation for this
discrepancy could be the use of different cell lines for testing
degradation. H1229 cells used in this study and Saos-2 used in
the previous study (Storey et al., 1998) may possess different
amounts of E6AP or different proteasome activities. In addition,
p53 Arg and p53 Pro may possibly have different conformations
in Saos-2 and H1299 cells, which could alter their susceptibility
to E6 (Medcalf and Milner, 1993). Consistent with the
degradation results are the data on inhibition of p53
transactivation, which also indicated similar levels of inhibition
of p53 Arg and p53 Pro by the E6 proteins.
Most of the tested E6 proteins exhibited high levels of
activity in degradation and inhibition of p53 TA. Some variants
showed small reduction in activity, but none of the variants was
completely impaired in p53 inactivation functions, indicating
the importance of these activities for the carcinogenic process.
Lower activity than the prototype E6 was consistently exhibited
by V2 (K11T) in degradation of p53 Pro and in inhibition of p53
Pro and p53 Arg TA. Reduced activity in inhibition of p53 Arg
transactivation was also displayed by V6 (Q14H/H78Y/L83V)
and V7 (R48W). Interestingly, V2 was detected only in one
biopsy (high-grade lesion) of the Swedish cohort out of 169
positive samples and in none of the other cohort samples (Zehbe
et al., 2001; Kammer et al., 2002). Similarly, V7 was detected
only in one cancer sample in the Italian population. V6
however, was represented, in all 3 cohorts, both in low- and
high-grade lesions (Zehbe et al., 2001).
None of the mutations tested in this study was tested in
previous studies with site directed mutants although other
amino acid changes in the same position, or in the vicinity of
those found in the naturally occurring mutants, have been
shown to impair the ability of E6 to induce p53 degradation.
Deletion of amino acids 9 to 13 or mutation of amino acids 8, 9,
and 10 of HPV16 E6 abolished the ability of the protein to
induce p53 degradation (Foster et al., 1994). Variants tested in
the present study that contained amino acid changes in position
8 (V9), 11 (V2), and 10 (V1) retained the prototype level of
degradation activity (V1 and V9) or showed a reduction in
activity (V2). In another study, K11E, which resemble V2
(K11T) was shown to be completely impaired in binding and
degradation of p53 in vitro and in vivo, in human keratinocytes,
and to have markedly reduced activity in Saos-2 cells (Cooper et
al., 2003). Similarly, the mutant Y54H that contains amino acid
change near that of V3 (N58S), and V7 (R48W) was completely
impaired in its ability to degrade p53 in vitro, in 37 °C, and in
vivo, in human mammary cells (Park and Androphy, 2002).Results of our study support the notion that HPV16 E6 can
accommodate some nonconservative changes in regions
important for the interaction with p53/AP, without large change
in its ability to target p53 for degradation and inhibit p53
transactivation. Apparently only such “functionally silent
mutations” towards p53 are selected in naturally occurring
mutants. This conclusion is also supported by results from other
studies that analyzed a small number of naturally occurring E6
variants, containing other amino acid alterations in the N-
terminal region of E6, which showed no loss or only small
reduction in E6 activity (Conrad Stoppler et al., 1996;
Matsumoto et al., 2000).
Similarly to the results on p53 degradation, variants tested in
this study showed comparable activities in Bax degradation.
Bax is an important regulator of apoptosis triggered by
genotoxic stimuli as well as other triggers (Cory and Adams,
2002). The ability of E6 to inhibit Bax induced apoptosis
suggests a potential function for E6 in circumventing cellular
signals for apoptosis (Shnitman-Magal et al., 2005). The N-
terminal amino acid residues required for this activity have not
been yet defined; however, mutations present in the natural
variants tested in this study only slightly reduced Bax
degradation activity. The multivariant, V10, that showed the
lowest activity still retained 0.8–0.9 of the prototype activity.
Interestingly, V8 and V5 (L83V and L83V+) displayed higher
activities than the prototype in Bax degradation. Additional
assays are needed to determine whether this enhanced activity is
associated with increased protection from Bax regulated
apoptosis.
Results of the in vitro binding assays with GST-BP and GST-
hDlg revealed more variable patterns of activity of the E6
proteins. Although all proteins were capable of binding to both
GST-fusions, differences in the average levels of activity among
variants, and between some variants and the prototype, were
detected. The prototype E6 exhibited moderate to high activity
in binding to these cellular targets. Different E6 variants were
found to have low or high binding activities in respect to the
different GST fusions.
Lowest binding to E6BP was displayed by V7 and V9, while
variants 2, 5, and 8 exhibited the highest E6BP binding, with
2.5- to 4.5-fold difference between the high and the low binding
proteins. Other studies that analyzed the binding efficiency of
site directed mutants showed that certain mutations in the N-
terminus of E6, such as L37S and Y54D, reduced binding to E6
BP but other mutations had no effect on E6 BP binding (Liu et
al., 1999). The data presented herein show that mutations
represented in V1 (K10G), V3 (N58S), V4 (R10G/L83V), V7
(R48W), and V9 (R8Q) reduced binding to E6BP (0.29 to 0.79
of the E6 PT activity).
It has been shown that binding to E6BP is the trait of the
high-risk E6 proteins. However, the role of E6-E6BP
association in cell transformation has not been yet defined.
Previous mutational analyses failed to establish the absolute
requirement of this association for transformation of mammary
epithelial cells (Liu et al., 1999) or formation of serum/calcium
resistant colonies in primary human keratinocytes (Sherman et
al., 2002). The isolation of E6 variants with reduced activities
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may not be a major determinant in E6 transformation. However,
it should be noted that the L83V polymorphism that was
associated with persistence (Londesborough et al., 1996) and
cancer in certain populations (Zehbe et al., 1998a, 1998b, 2001,
Kammer et al., 2002) exhibited high capacity of binding to
E6BP.
As indicated above, our studies show that binding to GST-
hDlg was less efficient as compared to GST-E6BP (about six-
fold). This result could result from the less strong association
between HPV E6 and hDlg and particularly that of HPV16 E6
(Kiyono et al., 1997). However, this could also be the result of
the experimental system employed for evaluation of the
association. In the present study, C-terminal epitope-tagged
proteins were used. Tagging causes a shift of the E6 PDZ-
binding domain from the distal C-terminal location. Although
the shift per se was previously shown to not affect the binding of
a deletion mutant of HPV18 E6 (144–149) (Pim et al., 2000),
tagging of HPV18 E6 with the AU-epitope was demonstrated to
impair degradation of the PDZ containing MAGI protein by
HPV18 E6 (Stewart et al., 2004). Results of the study herein
show that HA-tagged proteins were capable of binding to hDlg,
albeit at a low efficiency. Binding activities of the prototype E6
and most variants were at comparable levels. Variants 3 and
8 showed the lowest activity while variants 5 and 6 showed the
highest binding.
Binding of E6 to hDlg targets it for degradation (Gardiol et
al., 1999). Binding and degradation efficiencies of E6 proteins
were previously found to correlate (Kiyono et al., 1997; Gardiol
et al., 1999). Low binding of V8 to hDlg may suggest that this
function is less important in cell transformation, yet studies in
transgenic mouse models point to the necessity of the PDZ-
binding moiety for transformation (Nguyen et al., 2003). It is
possible that other PDZ proteins targets of E6 such as Scribble
or MAGI I–III are more important.
In summary, despite the limitations presented, this study
represents the most comprehensive and systematic attempt to
address functional alterations in the E6 proteins of naturally
occurring variants. The overall results indicate that changes in
the amino acid sequence of E6 can alter the level of activity of
the protein in functional assays relevant for its carcinogenic
potential. This provides a potential mechanism for risk of
transformation upon infection with certain variants. This study
revealed variants that exhibited statistically significant differ-
ences from the prototype E6 including variant 1 (lower binding
to E6BP), variant 2 (lower degradation of p53 Pro, lower
inhibition of p53 Arg/Pro transactivation) variant 6 (lower
inhibition of p53Arg transactivation), variant 7 (lower inhibi-
tion of p53 Arg transactivation and binding to E6BP), variant 9
(lower binding to E6BP). The L83V polymorphism (V8), which
is the most frequently detected variation, displayed moderate to
high activities in most functional assays that were comparable to
that of the E6 PT. Compared to the other variants, it showed
more efficient binding to E6BP, and more efficient degradation
of Bax, but lower binding to hDlg. When present in
combination with other amino acid changes (L83V+), overall
protein activity was influenced by the other amino acid changes.The non-European multi-variants, V6 and V10, also exhibited
levels of activity comparable to that of the E6 prototype in most
functional assays. It is possible that the assays employed in the
present study are not suitable to reveal subtle differences in
activity. On the other hand, these variants may have acquired a
selective advantage against immune pressure (Zehbe et al.,
2001, 2003; Chen et al., 2005) or altered biological properties,
which were not evaluated herein. Preliminary results obtained
from functional analyses that evaluated the abilities of the
variants to inhibit serum/calcium differentiation in human
keratinocytes indicated variable levels of activity. Activities of
the variants in the above assay did not absolutely correlate with
their activities in assays presented in this study. This is
consistent with previous data that demonstrated dissociation
of the serum/calcium differentiation inhibition function from E6
abilities to degrade p53, inhibit p53 transactivation and bind to
E6BP (Sherman et al., 2002). Additional studies are in progress
to determine whether E6 variants differ in their abilities to
deregulate the normal control of cell growth, apoptosis, and
differentiation in human keratinocytes and to identify the
molecular targets mediating these activities.
Materials and methods
Plasmids
Cloning into the expression vectors of the E6 BP cDNA and
GST-E6BP (Chen et al., 1995), the GST-hDlg fusion, pG EX
2TK-SAP97 (Lee et al., 1997), and cDNAs of the p53Pro (p53-
H-19) and p53 Arg (p53-H-1) (Harris et al., 1986), has been
described. The pJS55 and pJS55-GFP vectors were described
previously (Sparkowski et al., 1994; Sherman et al., 2002) and
so was the reporter plasmid encoding the firefly luciferase under
the human mdm2 (Zauberman et al., 1995).
The plasmid for expression of human Bax from the spleen
focus forming virus promoter (SFFV-Bax) was kindly provided
by S.J. Korsmeyer (Howard Hughes Medical Institute, MA,
USA). Renilla luciferase under the cytomegalovirus (CMV)
promoter was purchased from Promega. Isolation of the E6
genes of the HPV16 prototype and natural E6 variants
(nucleotides 52–575) from tissue samples was described
previously (Zehbe et al., 2001; Kammer et al., 2002). For
cloning, the E6 gene DNAs were amplified to include the EcoRI
and BglII sequences at the 5′ and 3′ ends, respectively, and then
cloned into the pLXSN vector in frame with the hemagglutinin
(HA1) tag sequence followed by a stop codon. Cloning into the
pLXSN vector was carried out in a stepwise procedure. First the
HA epitope sequence with the BglII and SalI sites sequences at
the 5′ and 3′ ends, respectively, was ligated to pLXSN (SalI/
XhoI), then the E6 DNAs were ligated upstream of the HA tag
via the EcoRI and Bgl II sites. For cloning into pJS55, the genes
of the prototype E6 and 10 variants were excised from the pLX
SN vectors and recloned into the EcoRI and BamHI sites of
pJS55 (Table 1). All vectors were analyzed by nucleotide
sequencing. Sequence analysis indicated that most variants
belong to the European lineage except variants 6 and 10 that
belong to the Asian–American lineage and the African 2 (Af2)
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mutation in the HA1 tag of variant 10 (Table 1) was detected.
This resulted in the expression of a truncated protein (5 amino
acids of the tag in place of 11 amino acids) that was not
recognized by the HA1 antibody.
Expression of the E6-variant proteins from the pJS55 vectors
was verified by transfection into COS cells and detection of the
proteins by immunoblot analysis with the HA1 antibody.
Cell culture and transfections
Human embryonic 293T cells and human lung carcinoma
H1299 cells were maintained in DMEM supplemented with
10% fetal calf serum. Cells were transfected by a modified
calcium phosphate procedure, as described (Sherman and
Schlegel, 1996).
p53 and Bax degradation assays in vivo
For p53 degradation, H1299 cells were cotransfected in
duplicates with 1 μg of the p53 expression plasmid, 0.5 or 5 μg
of the E6 test plasmid or empty vector, and 1 μg of pJS55-GFP
that was used as a control for transfection efficiency. For Bax
degradation, 293T cells were transfected with 2 μg of pSFFV-
Bax, 5 or 10 μg of the E6 test plasmid, and 1 μg of pJS55-GFP.
Cells were harvested after 48 h, and the remaining p53 or Bax
and GFP levels were determined by immunoblot analysis as
described (Sherman et al., 2002; Shnitman-Magal et al., 2005).
Degradation activity is presented as percent reduction of the p53
or Bax level (as detected in the empty vector transfected cells)
by the test E6 plasmid.
Immunoblotting analysis of protein abundance
Preparation of cell lysates in modified RIPA buffer,
electrophoresis on polyacrylamide gels, and transfer to nitro-
cellulose membranes were described previously (Shnitman-
Magal et al., 2005). Filters were cut into strips and reacted with
the specific antibodies. Primary antibodies used were as
follows: the Bax rabbit polyclonal antibody (SC-493; Santa
Cruz Biotechnology, Inc.), p53 DO-1 monoclonal antibody
(mAb) (SC-126; Santa Cruz Biotechnology, Inc.), HA rabbit
polyclonal antibody (y-11) (SC-805, Santa Cruz Biotechnology,
Inc.), the anti-GFP mAb mixture (Cat. No. 1 814460; Roche).
Proteins were visualized by enhanced chemiluminescence
(ECL) (Amersham), using peroxidase-conjugated anti-mouse
IgG (115-035-003) or goat anti-rabbit IgG (111-035-003);
Jackson Immuno Research Laboratories) according to the
manufacturer's instructions. Protein amounts were determined
by scanning of the films and analysis of the band intensities
using the TINA software. Nonsaturated exposures of ECL films
were used.
p53 transactivation assay
Inhibition of p53 transactivation was assessed by transfec-
tion of H1299 human cells with 0.5 μg of the p53 expressionplasmid, 0.5 μg of the hmdm2 luciferase reporter, 0.5 μg of the
Renilla luciferase, and 0.5 μg (or as otherwise indicated in the
text of the figures) of the E6 test plasmid. The cells were
harvested after 48 h. Firefly and Renilla luciferase activities
were determined with the dual luciferase assay kit (Promega),
and the firefly luciferase activity was normalized to the Renilla
luciferase activity. Inhibition of p53-dependent activity is
presented as percent reduction of the p53-dependent luciferase
activity (as detected in the vector transfected cells) by the test
E6 plasmid.
E6BP and hDlg in vitro binding assays
In vitro binding to E6BP and hDlg was tested in pull-down
assays as described previously for E6 BP (Chen et al., 1995;
Sherman et al., 2002). Briefly, 30 μl of glutathione-Sepharose
beads coupled to 2 μg of the GST-E6BP or GST fusion proteins
or 60 μl of beads coupled to 2 μg of the GST-hDlg or GST
proteins were incubated in 300 μl LSAB-binding buffer (100
mM NaC1, 100 mM Tris–HC1 (pH 8.0), 1% NP-40, 2 mM
dithiothreitol (DTT), 0.1% nonfat dry milk, and 1 mM
phenylmethylsulfonyl fluoride (PMSF)). The beads were
subjected to rotary shaking at 4 °C for 30 min, and then equal
amounts of each [35S]cysteine-methionine-labeled E6-variant
protein, translated in WGE (24 μl of the translation product),
was added to the respective GSTand GST fusion protein (E6 BP
or hDlg) beads, and rotation was continued for 2 h at 4 °C. After
incubation, the beads were washed four times with LSAB and
subjected to SDS-12,5% polyacrylamide gel electrophoresis. E6
binding was analyzed by autoradiography. One microliter of the
input protein was analyzed on a separate gel prior to the binding
reaction. The input gels were exposed overnight. Binding gels
were exposed for 4 days (E6 BP) or 12 days (hDlg). The
percentage of E6/mutant protein bound to GST-E6 was
calculated after subtracting the amount bound to the GST beads.
Statistical analysis
Data of activity in the various functional assays are presented
in the figures as average (mean) values ± SD. Data were
subjected to a one-way ANOVA. Significance was accepted at
P b 0.05.
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